Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC

Expert oncologists reflect on the evolving treatment paradigm for KRAS-mutated metastatic NSCLC with insight into data from ESMO 2023 and surrounding meetings, discussing targeted therapies and future perspectives in clinical practice.

EP. 1: The State of Targeted Therapies in NSCLC

November 30th 2023

Explore the current landscape of targeted therapies in non-small cell lung cancer, focusing on KRAS G12C mutations, molecular testing, and current treatments.

EP. 2: Frontline Treatments for KRAS G12C-Mutation mNSCLC

November 30th 2023

Experts review the current frontline treatments for patients with KRAS G12C-mutated NSCLC.

EP. 3: Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations

December 7th 2023

Shared insight into the consideration of KRAS G12C inhibitors in treating co-mutations in NSCLC.

EP. 4: The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC

December 7th 2023

Joshua K. Sabari, MD, and Edward B. Garon, MD, MS, discuss the role and potential impact of KRAS G12C inhibitors in the frontline setting, highlighting the potential of monotherapy and in combination with a PD-1/PD-L1 inhibitor.

EP. 5: Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition

December 14th 2023

A comprehensive review of hepatotoxicity in ongoing studies evaluating KRAS inhibitors in the frontline setting, highlighting adagrasib and sotorasib in the KRYSTAL-7 and CodeBreaK 100 studies, respectively.

EP. 6: Disease Progression Beyond Frontline KRAS G12C Inhibitors

December 14th 2023

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.

EP. 7: CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

December 21st 2023

Dr. Sabari and Dr. Garon discuss second line sotorasib and the results of the CodeBreaK 200 study, highlighting the recent FDA oncologic drugs advisory committee (ODAC) and their assessment of the study results.

EP. 8: KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

December 21st 2023

Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.

EP. 9: Practical Management of Hepatotoxicity in KRAS G12C Inhibitors

December 28th 2023

Shared insight on the clinical management of hepatotoxicity with use of KRAS G12C inhibitors in mNSCLC.

EP. 10: Future Perspectives in KRAS G12C-Mutated NSCLC

December 28th 2023

In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.